The global T-cell Lymphoma Market is estimated to be valued at US$ 1961.64 Mn in 2023 and is expected to exhibit a CAGR of 9.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
T-cell lymphoma is a type of Non-Hodgkin’s lymphoma caused by abnormal T lymphocytes. It can affect both children and adults. The main types of T-cell lymphoma are T-cell prolymphocytic leukemia, adult T-cell leukemia/lymphoma, and other types including anaplastic, angioimmunoblastic, and others. Therapeutics for T-cell lymphoma includes chemotherapy, radiation therapy, targeted therapy, stem cell transplantation, etc. Growing research activities to develop targeted and immunotherapy for difficult-to-treat T-cell lymphoma is propelling the market growth.
Market key trends:
One of the key trends in the T-cell lymphoma market size is increasing approval and launch of novel therapies. For instance, in 2018, FDA approved romidepsin (Istodax) for peripheral T-cell lymphoma and cutaneous T-cell lymphoma. In 2022, FDA approved tafasitamab-cxix (Monjuvi) in combination with lenalidomide for relapsed or refractory diffuse large B-cell lymphoma. Development of chimeric antigen receptor T cell (CAR-T) therapy is also a major focus area to address unmet needs in T-cell lymphoma treatment. Bristol-Myers Squibb’s brexucabtagene autoleucel (Tecartus) received FDA approval in 2021 for relapsed or refractory mantle cell lymphoma. Increasing research collaborations to develop differentiated therapy options is another trend expected to accelerate growth of this market over the forecast period.
Threat of new entrants: The threat is moderate as the T-cell lymphoma market requires high R&D investments and clinical trials for new drug development. Bargaining power of buyers: The bargaining power is high due to presence of many therapy options and generic drugs. Bargaining power of suppliers: The bargaining power of suppliers is moderate due to availability of substitutes. Threat of new substitutes: The threat is high as new small molecule therapies and monoclonal antibodies are entering the market. Competitive rivalry: Intense due to presence of many global and regional players.
The global T-cell lymphoma market is expected to witness high growth, exhibiting CAGR of 9.8% over the forecast period, due to increasing preference for targeted therapies and growing R&D investments by key players.
Regional analysis: North America is expected to dominate the global T-cell lymphoma market over the forecast period owing to increasing healthcare expenditure and presence of key market players in the region. However, Asia Pacific is anticipated to exhibit the fastest growth rate during the forecast period owing to rising healthcare infrastructure, constantly improving standard of living, and growing penetration of targeted drugs.
Key players operating in the T-cell lymphoma market are F. Hoffmann-La Roche Ltd, Biocryst Pharmaceuticals Inc., Bristol-Myers Squibb Company, Kyowa Kirin Co., Ltd., Genmab A/S, Seagen Inc., GlaxoSmithKline plc., Johnson and Johnson Private Limited, Elorac, Acrotech Biopharma, Merck and Co. Inc., Novartis AG, SHIONOGI & Co., Ltd., Spectrum Pharmaceuticals Inc., and Bausch Health Companies Inc. Key players are majorly focusing on R&D activities to develop novel targeted therapies for treatment of T-cell lymphoma.